The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy (Q35990705)

11 August 2017

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy (English)

1 reference

heparan sulfate proteoglycans

11 August 2017

1 reference

16

Bart Barlogie

1 reference

11 August 2017

14

Shmuel Yaccoby

1 reference

11 August 2017

Yang Yang

1

1 reference

11 August 2017

Veronica MacLeod

2

1 reference

11 August 2017

Yuemeng Dai

3

1 reference

11 August 2017

Yekaterina Khotskaya-Sample

4

1 reference

11 August 2017

Zachary Shriver

5

1 reference

11 August 2017

Ganesh Venkataraman

6

1 reference

11 August 2017

Ram Sasisekharan

7

1 reference

11 August 2017

Annamaria Naggi

8

1 reference

11 August 2017

Giangiacomo Torri

9

1 reference

11 August 2017

Benito Casu

10

1 reference

11 August 2017

Israel Vlodavsky

11

1 reference

11 August 2017

Larry J Suva

12

1 reference

11 August 2017

Joshua Epstein

13

1 reference

11 August 2017

John D Shaughnessy

15

1 reference

11 August 2017

Ralph D Sanderson

17

1 reference

11 August 2017

language of work or name

English

0 references

publication date

29 May 2007

1 reference

11 August 2017

1 reference

11 August 2017

110

1 reference

11 August 2017

2041-2048

1 reference

11 August 2017

6

1 reference

Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Synopsis of a roundtable on validating novel therapeutics for multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Development of heparanase inhibitors for anti-cancer therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

The role of heparan sulphate proteoglycans in angiogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Decreasing the metastatic potential in cancers--targeting the heparan sulfate proteoglycans

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Characterization of clonogenic multiple myeloma cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Bone is a target for the antidiabetic compound rosiglitazone.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Soluble syndecan-1 promotes growth of myeloma tumors in vivo

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Multiple heparan sulfate chains are required for optimal syndecan-1 function

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Requirement of vascular integrin alpha v beta 3 for angiogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1976367

Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma

23 September 2018

1 reference

12 December 2020

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

12 December 2020

High heparanase activity in multiple myeloma is associated with elevated microvessel density

1 reference

12 December 2020

Heparanase promotes the spontaneous metastasis of myeloma cells to bone

1 reference

12 December 2020

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival

1 reference

12 December 2020

Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis

1 reference

12 December 2020

Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis

1 reference

12 December 2020

Serum syndecan-1: a new independent prognostic marker in multiple myeloma

1 reference

12 December 2020

Histidine 295 and histidine 510 are crucial for the enzymatic degradation of heparan sulfate by heparinase III

1 reference

12 December 2020

A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1

1 reference

12 December 2020

Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma

1 reference

12 December 2020

The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity

1 reference

12 December 2020

Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations

1 reference

12 December 2020

SCID-hu mice for the study of human cancer metastasis

1 reference

12 December 2020

10.1182/BLOOD-2007-04-082495

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

1 reference